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Loss of extracellular superoxide dismutase leads to acute lung
damage in the presence of ambient air: a potential mechanism
underlying adult respiratory distress syndrome
Abstract
The extracellular superoxide dismutase 3 (SOD3) is highly expressed in both blood vessels and lungs. In
different models of pulmonary injury, SOD3 is reduced; however, it is unclear whether this contributes
to lung injury. To study the role of acute SOD3 reduction in lung injury, the SOD3 gene was deleted in
adult mice by using the Cre-Lox technology. Acute reduction of SOD3 led to a fivefold increase in lung
superoxide, marked inflammatory cell infiltration, a threefold increase in the arterial-alveolar gradient,
respiratory acidosis, histological changes similar to those observed in adult respiratory distress
syndrome, and 85% mortality. Treatment with the SOD mimetic MnTBAP and intranasal administration
of SOD-containing polyketal microparticles reduced mortality, prevented the histological alterations,
and reduced lung superoxide levels. To understand how mice with the SOD3 embryonic deletion
survived without lung injury, gene array analysis was performed. These data demonstrated the
up-regulation of 37 genes and down-regulation of nine genes, including those involved in cell signaling,
inflammation, and gene transcription in SOD3-/- mice compared with either mice with acute SOD3
reduction or wild-type controls. These studies show that SOD3 is essential for survival in the presence
of ambient oxygen and that acute loss of this enzyme can lead to severe lung damage. Strategies either
to prevent SOD3 inactivation or to augment its levels might prove useful in the treatment of acute lung
injury.
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The extracellular superoxide dismutase 3 (SOD3) is
highly expressed in both blood vessels and lungs. In
different models of pulmonary injury, SOD3 is re-
duced; however, it is unclear whether this contributes
to lung injury. To study the role of acute SOD3 reduc-
tion in lung injury, the SOD3 gene was deleted in
adult mice by using the Cre-Lox technology. Acute
reduction of SOD3 led to a fivefold increase in lung
superoxide, marked inflammatory cell infiltration, a
threefold increase in the arterial-alveolar gradient,
respiratory acidosis, histological changes similar to
those observed in adult respiratory distress syn-
drome, and 85% mortality. Treatment with the SOD
mimetic MnTBAP and intranasal administration of
SOD-containing polyketal microparticles reduced
mortality, prevented the histological alterations, and
reduced lung superoxide levels. To understand how
mice with the SOD3 embryonic deletion survived
without lung injury, gene array analysis was per-
formed. These data demonstrated the up-regulation of
37 genes and down-regulation of nine genes, includ-
ing those involved in cell signaling, inflammation,
and gene transcription in SOD3/ mice compared
with either mice with acute SOD3 reduction or wild-
type controls. These studies show that SOD3 is essen-
tial for survival in the presence of ambient oxygen
and that acute loss of this enzyme can lead to severe
lung damage. Strategies either to prevent SOD3 in-
activation or to augment its levels might prove use-
ful in the treatment of acute lung injury. (Am J
Pathol 2008, 173:915–926; DOI: 10.2353/ajpath.2008.080119)
The superoxide dismutases (SODs) are major defenses
against oxidative damage caused by the superoxide an-
ion (O2
.).1 There are three isoforms of SOD in mammalian
cells. In most tissues, the copper/zinc superoxide dis-
mutase (Cu/ZnSOD or SOD1), a cytoplasmic copper-
containing enzyme, is predominant. Mice lacking SOD1
are predisposed to hepatic fat deposition, hepatic tumor
development, motor neuron disease, abnormal vascular
function, and vascular hypertrophy.2–6 Manganese su-
peroxide dismutase (MnSOD or SOD2) is localized to the
mitochondria, where it plays a major role in defending
against O2
. generated as a co-product of electron trans-
port.7 Mice lacking MnSOD die of a cardiomyopathy
within the first 10 days of life.8 The last discovered of the
SOD isoforms is extracellular superoxide dismutase, or
SOD3. SOD3 is similar to SOD1 in that it is a copper/zinc-
containing enzyme; however, it contains a signal se-
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quence that targets it to the Golgi secretory apparatus
and it is loaded with copper via two novel proteins, Atox-1
and Menkes.9 SOD3 is secreted via the trans-Golgi net-
work and is bound to components of the extracellular
matrix including heparin binding sites, fibullin-5,10 colla-
gen-I, and hyaluronan.11–13 While SOD3 represents less
than 5% of the total SOD in most cells, it is highly ex-
pressed in the lung.14,15
The adult respiratory distress syndrome represents a
major cause of morbidity and mortality in hospitalized
patients and is observed in the setting of diverse clinical
insults, including sepsis, hemorrhage, surgery, trauma,
and extensive transfusion. The precise mechanisms
whereby these various clinical entities predispose to lung
injury remain poorly defined. Of note, several experimen-
tal models of lung injury, including hypoxia, asbestos
exposure, bleomycin, and hyperoxia, are associated with
reduced lung SOD3 protein and activity.16–19 These
studies suggest that extracellular oxidative stress con-
tributes to the pathogenesis of acute lung injury and that
SOD3 protects against it.19–22
In these cases of lung injury, it is unclear whether the
loss of SOD3 contributes to or is simply a consequence of
lung injury. Of note, lung injury caused by exposure to
100% oxygen is hastened in mice with embryonic dele-
tion of SOD3 (SOD3/ mice). Embryonic SOD3/ mice
tolerate exposure to ambient oxygen levels without diffi-
culty; however, they have had a life-time to compensate
for any deleterious effects of SOD3 deletion. These ani-
mals are therefore not informative in determining the role
of acute SOD3 reduction in causing lung damage in the
presence of normal oxygen concentrations.
The present study was performed to accomplish the
following goals. First, we sought to determine whether
acute reductions in SOD3, similar to that observed in
experimental models of lung damage, could cause lung
injury without exposure to hyperoxia. Second, we sought
to develop a method of delivering exogenous SOD to
prevent lung damage. To this end, we developed a novel
polyketal particle that could be delivered intranasally and
that could release SOD slowly over several days. Third, we
examined potential compensatory mechanisms present in
mice with embryonic deletion of SOD3 that could potentially
prevent lung damage in these animals.
Materials and Methods
Creation and Study of Tgcre/esr  ecSODloxp/loxp
Mice
The targeting vector was created by modifying a 6.12-kb
HindIII fragment of the mouse SOD3 gene obtained from
the BAC clone 229-C-20 on vector pBeloBAC (Genome
Systems, St. Louis, MO). This was extended by cloning
an additional 3 kb into the 5 end. A single loxP site was
inserted into intron 1 at the AatII site and a loxP-flanked
neomycin resistance cassette was inserted at ApaI site 3
of exon 2. All three loxP sites were in the same orientation.
The targeting vector used for homologous recombination
was 10.7 kbp in length and the 5 and 3homologous
sequences for targeting were 4.43 kb and 1.23 kb,
respectively.
Electroporation of the linearized DNA fragment into
embryonic stem cells yielded 306 clones resistant to
G418. Southern blotting using a probe external to the
targeting vector indicated that two clones had successful
recombination. The neomycin cassette was removed by
transfection of embryonic stem cells with Cre-recombi-
nase containing plasmid, yielding cells that harbored a
SOD3 targeted allele (see Supplemental Figure 1 avail-
able at http://ajp.amjpathol.org). A high percentage of
chimeric mice were generated by blast injection and
were bred to C57BL/6 mice to allow germ line transmis-
sion of the floxed SOD3 allele. Heterozygous ecSODloxp
offspring were backcrossed six generations to C57BL/6
wild-type mice before being crossed to the tamoxifen-Cre
transgenic mice. These were then intercrossed a second
time to generate Tgcre/esr  ecSODloxp/loxp experimental
animals. The control group for experiments was C57Bl/6
mice that were purchased from the Jackson Laboratory
(Bar Harbor, Maine). Mice were fed with regular chow
diet (LabDiet, rodent diet no. 5001) ad libitum and studied
between 10 and 12 weeks of age after CO2 euthanization.
The Emory University Animal Care and Use Committee
approved the protocol for animal use. Experiments were
performed when mice were 3 months of age.
Measurement of Blood Gases, Blood Pressure,
and Cardiac Contractility
Mice were anesthetized with 1% to 2% isoflurane in 100%
O2, the abdomen opened, and 150 l of blood was
collected from the abdominal aorta into a heparinized
syringe and analyzed on an ABL5 blood gas analyzer
(Radiometer Copenhagen). Arterial blood samples were
obtained as soon as the animals became ill. Total anes-
thesia time was held constant in mice from each treat-
ment group. Partial pressures of oxygen, CO2, and pH
were measured to calculate arterial-alveolar gradient.
Blood pressure was measured noninvasively via the tail
cuff method and invasively using radiotelemetry as pre-
viously described.23 Cardiac function was evaluated us-
ing the Siemens Sequoia Acuson 512 Sonograph (Sie-
mens, Mountain View, CA) and 15L8 linear transducer
(14 MHz). Two-dimensional images were acquired at a
depth setting of 2 cm.
Tamoxifen Injection and Administration of
MnTBAP and SOD Microparticles
Cre-recombinase was activated by the intraperitoneal
injection of tamoxifen (3 mg/20 g of body weight) for 5
consecutive days. Control mice were studied in parallel.
These animals received injections with an equivalent vol-
ume of the vehicle, corn oil, for 5 consecutive days. As
another control, C57BL/6 mice were treated for a similar
period of time with tamoxifen. In some experiments, the
SOD mimetic MnTBAP (Calbiochem catalog no. 475870,
purity 95%, 1 mg/20 g of body weight) was injected
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intraperitoneally daily starting 2 days before tamoxifen
injection, during tamoxifen treatment, and for 7 days after
tamoxifen treatment. In other experiments, 80 l of
polyketal particles containing SOD (5 mg/ml, described
below) were administrated intranasally while mice were
briefly anesthetized with isoflurane (2%).
Histology and Immunostaining
After CO2 euthanization, a cannula was placed in the left
ventricle and the mice were initially perfused at 100
mmHg with saline to remove blood and then with 10%
formaldehyde. Lungs and other organs were harvested
after 10 minutes of perfusion and preserved in formalde-
hyde until embedded in paraffin, sectioned, and immu-
nostained for SOD3 using a rabbit polyclonal antibody
against SOD3 previously described.24
Flow Cytometry Analysis of Lung
Inflammatory Cells
Lungs were cleared of blood by perfusion with phos-
phate-buffered saline (PBS), excised, and digested using
collagenase type IX (125 U/ml), collagenase type IS (450
U/ml), and hyaluronidase IS (60 U/ml) dissolved in
20 mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfo-
nic acid-PBS buffer containing calcium. The digested
tissue was then passed through a 70-m sterile cell
strainer (Falcon, BD), yielding single cell suspensions.
Cell labeling was performed using the following antibod-
ies (all from BD PharMingen, apart from CD49b): fluores-
cein isothiocyanate anti-CD45 (30-F11); PerCP anti-CD45
(30-F11); PE anti-CD4 (GK1.5); APC anti-CD4 (GK1.5);
PerCP anti-CD8 (53-6.7); APC anti-CD3 (145-2C11); flu-
orescein isothiocyanate anti-I-Ab (AF6-120.1); APC anti-
CD11c (HL3); APC CD11b (M1/70); APC CD4 (RM4-5);
PerCP CD4 (RM4-5); PE NK1.1 (PK136); PE CD49b
(eBioscience). Cells were washed twice with 1% bovine
serum albumin-PBS buffer and additionally incubated for
30 minutes in 37°C with complete media (RPMI 1640 with
10% fetal calf serum). Fluorescence-activated cell sorting
analysis was performed using a Becton Dickson LSRII
flow cytometer. An initial gate was applied to exclude cell
debris from further analysis, and CD45 staining was used
to identify leukocytes within the aortic cell suspension.
Within the CD45 gate individual subpopulations of
leukocytes were identified with antibodies listed above.
Data were analyzed using Flowjo software (Treestar)
and expressed as an absolute number of cells per two
lungs.
Western Blots and SOD Activity
Protein expression was examined using Western blot
analysis as previously described. Antibodies used were
the following: anti-SOD1 from Biodesign International; anti-
SOD2 from Stressgen; and anti-SOD3 as previously de-
scribed.24 Equal gel loading was determined by blotting
for -actin (Sigma). Activity of SOD isoforms was deter-
mined spectrophotometrically by monitoring the inhibition
of the rate of xanthine oxidase-mediated reduction of
cytochrome c. SOD3 was separated from intracellular
SOD with concavalin A as described previously.24
Detection of Extracellular Superoxide Using
Electron Spin Resonance
To detect lung O2
. production, we used electron spin
resonance spectroscopy with the CAT1H spin probe as
previously described.25 The SOD-inhibited amplitude of
the low-field component of the electron spin resonance
spectra of oxidized CAT1H was used to quantify extra-
cellular O2
. production. Values were normalized to dry
weight.
Formulation of SOD-Loaded Microparticles
SOD-loaded microparticles were formulated from the acid-
sensitive polymer poly(cyclohexane-1,4-diyl acetone
dimethylene ketal) using a modified water-in-oil-in-water
(w/o/w) double-emulsion procedure. As reported previ-
ously, SOD-loaded poly(cyclohexane-1,4-diyl acetone
dimethylene ketal) microparticles degrade in acidic en-
vironments and have been shown to decrease cellular
superoxide in vitro.26 Briefly, 15 mg of SOD (Sigma) was
dissolved in 75 l of a 2.5% (w/v) polyvinyl alcohol
(Sigma, 31–50 kd) solution prepared from a pH 8.0 so-
dium phosphate buffer (0.1 mol/L). This aqueous SOD/
polyvinyl alcohol solution was dispersed via homogeni-
zation (21,000 rpm for 60 seconds.) into 1.0 ml of a 15%
(w/v) poly(cyclohexane-1,4-diyl acetone dimethylene ketal)/
CHCl3 solution, generating the w/o primary emulsion.
This SOD-containing w/o emulsion was then transferred
by pipette to the bottom of a 24-ml vial containing 15 ml
of an aqueous 5% (w/v) polyvinyl alcohol solution and
homogenized (9500 rpm for 90 seconds.) to produce the
w/o/w secondary emulsion. This w/o/w emulsion was then
poured into a stirred 5% polyvinyl alcohol solution buff-
ered at pH 8.0 by a 0.1 mol/L sodium phosphate buffer.
This mixture was then continuously stirred for 3 hours to
allow the CHCl3 to evaporate, leaving the polymer hard-
ened around the SOD to generate SOD microparticles.
To remove the excess polyvinyl alcohol, the hardened
particles were transferred to 50-ml centrifuged tubes and
washed by successively isolating the particles via cen-
trifugation, decanting the supernatant, and then resus-
pending the particles in distilled water. The particles were
washed three times and then freeze-dried, producing
approximately 30 mg of SOD microparticles. A scanning
electron microscopic image of the SOD microparticles
(see Supplemental Figure 2 available at http://ajp.
amjpathol.org) shows that these particles have diameters
from 1 to 25 m, with the majority of the particles having
diameters in the 5- to 20-m range.
The amount of SOD loaded into the particles was de-
termined by a commercially available BCA protein assay
kit (BioRad) using the following procedure. The encap-
sulated SOD was recovered from the microparticles by
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hydrolyzing 5 mg of SOD microparticles in a 1 N HCl
solution containing 2% (w/v) sodium dodecyl sulfate to
hydrolyze the acid-sensitive poly(cyclohexane-1,4-diyl
acetone dimethylene ketal) polymer. This acidic solution
was the neutralized with 1 N NaOH and assayed for
protein content using the BCA protein assay with various
concentrations of SOD in 1% sodium dodecyl sulfate that
had been acidified and subsequently neutralized as a
standard. The protein loading assays showed that each
milligram of SOD microparticles contained 32.1 g of
SOD. Further details regarding these microparticles have
been described previously.27
Statistical Analysis
Data are expressed as means  SEM. Comparisons
between groups were performed using analysis of vari-
ance and a Bonferroni/Dunn post hoc test for comparison
of selected groups.
Results
Conditional Reduction of SOD3
Tgcre/esr ecSODloxp/loxp mice were phenotypically iden-
tical to C57BL/6 mice. Administration of tamoxifen had no
effect on C57BL/6 mice or on ecSODloxp/loxp mice not
harboring Cre-recombinase. Likewise, administration of vehi-
cle (corn oil) to either C57BL/6 or Tgcre/esr  ecSODloxp/loxp
mice had no effect on survival. In contrast, administration
of tamoxifen to Tgcre/esr  ecSODloxp/loxp mice led to
striking mortality such that 85% of mice died within 7 days
(Figure 1). The pattern of death in these animals was
characterized by normal behavior without any evidence
of illness until a few hours before death, when they be-
came hunched, demonstrated limited motion, had tachy-
pnea, and died shortly thereafter. After recognizing this,
we began to sacrifice mice at the time that they became
ill and harvest organs for study. The control animals
(C57BL/6 receiving vehicle and tamoxifen and Tgcre/esr
ecSODloxp/loxp mice receiving vehicle) were euthanized
in parallel at this time. In general, this was between 3 and
7 days following onset of tamoxifen injections. Data in the
figures therefore represent these time points.
Tamoxifen treatment reduced SOD3 protein without
altering SOD1 levels in lungs of Tgcre/esr ecSODloxp/loxp
mice while having no effect in C57BL/6 mice (Figure 2A).
The decrease in SOD3 protein was paralleled by a re-
duction in its enzymatic activity, while there was no
change in activity of intracellular SOD isoforms (Figure
2B). Polymerase chain reaction, using primers external to
the loxP sites flanking exon 3, confirmed deletion of this
exon following 5 days of tamoxifen injection (see Supple-
mental Figure 3 available at http://ajp.amjpathol.org). Im-
munostaining also showed a marked decrease in lung
SOD3 following tamoxifen administration in Tgcre/esr 
ecSODloxp/loxp mice with no change in C57BL/6 mice
(Figure 2C). This reduction of lung SOD3 was associated
with a marked increase in lung O2
. levels as measured
using electron spin resonance (Figure 2D). Treatment
with MnTBAP, while not inhibiting scission of exon 3,
prevented this increase in O2
. (Figure 2D and Supplemen-
tal Figure 3 available at http://ajp.amjpathol.org).
SOD3 Reduction Induces Lung Damage
Histological examination of the heart (Figure 3A), aorta
(Figure 3B), kidney, and liver (data not shown) revealed
no significant pathology in Tgcre/esr  ecSODloxp/loxp
mice following tamoxifen injection. Likewise, lung struc-
ture was not altered in C57BL/6 mice given either vehicle
or tamoxifen or in Tgcre/esr  ecSODloxp/loxp mice given
vehicle (Figure 3C). In contrast, administration of tamox-
ifen to Tgcre/esr  ecSODloxp/loxp mice caused a striking
alteration of lung histology, with thickening of the alveolar
septa, a marked inflammatory cell infiltrate, hemorrhage into
the alveoli, and loss of patent alveoli (Figure 3, C and D).
Acute reduction of SOD3 was associated with a strik-
ing increase in lung levels of granulocytes, T cells, and
natural killer cells. Among T cells, CD8 and to a lesser extent
CD4 cells were increased (Figure 4). Reduction of SOD3
did not change lung content of dendritic cells, B cells, or
macrophages (data not shown). Injection of tamoxifen in
C57BL/6 mice or vehicle in to Tgcre/esr  ecSODloxp/loxp
mice had no effect on lung inflammatory cells.
In additional studies, we measured arterial blood
gases while the mice were anesthetized with isoflurane
and breathing 100% O2. Deletion of the SOD3 gene re-
sulted in a reduction in pO2 and pH, an increase in pCO2,
and a marked widening of the arterial-alveolar oxygen gra-
dient (Table 1). Neither tamoxifen nor vehicle altered these
parameters in C57BL/6 mice, and vehicle had no effect on


















Figure 1. Effect of SOD3 deletion on survival. C57BL/6 and Tgcre/esr 
ecSODloxp/loxp mice were injected with tamoxifen (3 mg/20 g of body
weight) or vehicle (equivalent volume of corn oil) intraperitoneally for 5
consecutive days. In additional experiments conditional SOD3 deletion, mice
lacking the cre/esr transgene (Cre/) were injected with tamoxifen.
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Effect of Systemic and Locally Administered
SOD on Survival and Lung Histology
In other experiments we determined if either systemic or
local administration of antioxidants could prevent lung
injury and mortality caused by deletion of ecSOD. Co-
treatment of Tgcre/esr  ecSODloxp/loxp mice with tamox-
ifen and intraperitoneal MnTBAP markedly reduced mor-
tality and lung injury caused by SOD3 reduction (Figure
5,A and B). To directly demonstrate that pulmonary aug-
mentation of SOD activity could prevent mortality and
lung damage in these animals, we administered polyketal
microparticles containing SOD1 via an intranasal route.
This treatment also reduced mortality and alterations of
lung morphology caused by acute SOD3 depletion (Fig-
ure 5B). Taken together, these data illustrate that a rela-
tively moderate (50%) reduction of SOD3 in adult animals
causes severe lung damage and death and that this can
be prevented by either systemic augmentation of superox-
ide scavenging or by directed pulmonary delivery of SOD.
In additional experiments, we examined the effect of
acute deletion of SOD3 on hemodynamics. Previous
studies have shown that mice with embryonic knockout of
SOD3 have normal blood pressure at baseline, but de-
velop augmented hypertension during angiotensin II in-
fusion.25 Moreover, their aortas have higher levels of O2
.
and abnormal endothelium-dependent vasodilatation at
baseline. We sought to determine whether acute deletion
of SOD3 would cause an acute increase in blood pressure.
Before the day on which the Tgcre/esr  ecSODloxp/loxp mice
became ill, blood pressure was not affected by tamoxifen
injection as measured either noninvasively by the tail
cuff method or invasively by radiotelemetry (Figure
6A). Likewise, cardiac contractility measured by echocardi-
ography was preserved in Tgcre/esr  ecSODloxp/loxp mice
even when the animals became ill (Figure 6B).
To provide an understanding of compensatory mech-
anisms that might allow mice embryonically deleted
SOD3 to survive, we compared mRNAs expressed in the
lungs of mice with embryonic deletion of SOD3 to those in
Figure 2. Effect of Cre-recombinase induction on SOD levels and activity and O2
. levels in Tgcre/esr ecSODloxp/loxp mice. A:Western blot showing protein levels
of SOD1 and SOD3 in lung tissue of C57BL/6 and Tgcre/esr  ecSODloxp/loxp mice injected with either tamoxifen or vehicle. B: Effect of SOD3 depletion on
intracellular SODs and SOD3 enzymatic activity in Tgcre/esr ecSODloxp/loxp and C57BL/6 mouse lung. Lung tissue was homogenized and SOD isoforms separated
as described in the text. SOD activity was determined by measuring the ability to inhibit xanthine/xanthine oxidase cytochrome c reduction. Data are the means
of three experiments. C: Immunohistochemistry and hematoxylin and eosin staining for SOD3 in lungs of C57BL/6 and Tgcre/esr  ecSODloxp/loxp mice injected
with tamoxifen (magnification, 40). D: Effect of SOD3 reduction on O2
. production in C57BL/6 and Tgcre/esr  ecSODloxp/loxp mice. Three or four 1-mm-thick
slices were incubated in buffer containing the CAT1H probe for one hour at 37°C. Parallel slices were incubated with CAT1H and Cu/ZnSOD (100 U/ml). Aliquots
of buffer were then examined using electron spin resonance (n  6 or 7 per group).
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either normal wild-type mouse lungs or our Tgcre/esr 
ecSODloxp/loxp mice following tamoxifen injection using
gene array studies. This analysis revealed 37 genes that
were up-regulated in mice with embryonic deletion of
SOD3 by more than twofold compared to either of the
other groups (Table 2).
Discussion
There are several important new findings derived from
the current study. First, in the presence of normal oxygen
tension, an acute reduction of SOD3 causes severe lung
disease. This adds to our current understanding of the
role of SOD3, because prior studies of mice with embry-
onic deletion of SOD3 showed that lung damage only
occurred on exposure to 100% oxygen or challenged
with other insults. Our findings that acute loss of this
protein in adult animals might have implications for other
etiologies of lung disease, where SOD3 is also reduced.
Second, we developed a novel method of locally deliver-
ing exogenous SOD using polyketal particles that was
effective in preventing lung disease. Given the similarity
between the lung damage observed in our Tgcre/esr 
ecSODloxp/loxp mice and other models of acute lung in-
jury, such a therapeutic approach might prove effective
in treating additional causes of pulmonary injury. Third,
our gene array analysis show a striking change in mRNA
expression in the lungs of mice with embryonic SOD
deletion, providing some insight into how mammals can
compensate for a life-long loss of this gene.
The earth formed approximately 4.5 billion years ago,
and it has been estimated that it was anoxic until about
2.3 billion years ago.28 At that time, the first photosyn-
thetic organisms, cyanobacteria, became capable of
photosynthesis, leading to a sudden increase in oxygen
in the oceans and atmosphere. This triggered the devel-
opment of complex multicellular organisms that de-
pended on oxygen;29 however, a very complex biology
arose as a result of this involving utilization of oxygen and
protection against oxygen metabolites. Prokaryotic and
eukaryotic cells adapted small molecules as antioxidants
and developed enzymes that produce, scavenge, and
Figure 3. Effect of SOD3 deletion on histology of the heart, aorta, and lungs. Hematoxylin and eosin staining of 5-m paraffin-embedded slides of myocardium
(A, 10); aorta (B, 4); and lung (C, 40) following either tamoxifen or vehicle injection (10). D shows a higher magnification (63) of eosin-stained lung
with neutrophils, lymphocytes, and other inflammatory cells visible.
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use reactive oxygen species and other enzymes that can
prevent and repair oxidative damage. Interestingly, some
of these enzymes are highly preserved from bacteria to
humans, supporting the concept that the coexistence
with oxygen metabolites has been essential for millions of
years. One such adaptation that developed in mammals
was expression of SOD3 in high amounts in specific
organs such as blood vessels30 and the lung.9 The
present study shows that SOD3 is essential for survival in
the presence of ambient oxygen and that acute deletion
of this gene leads to severe acute lung disease. This is
associated with a widening of the arterial-alveolar oxygen
gradient, a reduction in blood oxygen partial pressure, an
increase in plasma CO2, and ultimately death. Systemic
treatment with the SOD mimetic MnTBAP or local admin-
istration of microparticles containing SOD reduced mor-
tality in these animals and preserved lung architecture.
We speculate that these novel SOD carrier microparticles
could reduce lung damage and mortality in human lung
injury. It has been proposed that SOD mimetics might
have a protective role against smoking-induced lung in-
jury and COPD in humans.31 Specific SOD3 polymor-
phisms have also been associated with varying courses
of idiopathic pulmonary fibrosis in humans, further sup-
porting the role of this protein in protecting against lung
disease.32 We propose that loss of SOD3 might underlie
the progression of lung disease observed following di-
verse stimuli that would impose an initial oxidant stress,
such as infection, radiation, hemorrhage, or trauma.
The highest oxygen tension encountered in vivo is at
the alveolar surface, and these high levels of oxygen
could serve as a substrate for reactive oxygen species-
Figure 4. Lung infiltration of inflammatory cells following reduction of SOD3. Lungs were cleared of blood by perfusion with PBS, excised, and digested using
collagenase and hyaluronidase as described in Materials and Methods. The homogenates were dissolved in 20 mmol/L 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid-PBS and passed through a 70-m sterile cell strainer, yielding single cell suspensions. Cells were immunostained, resuspended in fluorescence-
activated cell sorting buffer, and immediately analyzed via flow cytometry.
Table 1. Arterial Blood Gases in C57BL/6 and Tgcre/esr  ecSODloxp/loxp Mice Injected with Tamoxifen or Vehicle
pH pO2 (mmHg) pCO2 (mmHg) Arterial-alveolar gradient (mmHg)
C57Bl6 vehicle 7.37  0.01 545  40 38  1 78  20
C57Bl6 tamoxifen 7.36  0.02 596  26 42  4 55  27
Conditional vehicle 7.37  0.01 581  19 42  1 79  19
Conditional tamoxifen 7.23  0.05*† 409  67† 53  3† 237  67*†
*P 	 0.05 versus vehicle injection.
†P 	 0.05 versus C57BL/6 mice treated with tamoxifen.
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generating enzymes such as NADPH oxidases within
macrophages or in alveolar epithelial cells,33 mitochon-
dria in epithelial cells,34 or xanthine oxidase in epithelial
cells.35 The presence of O2
.-scavenging enzymes would
therefore seem to be critical at this site. Indeed, previous
studies have shown that the alveolar surface is the major
site of lung SOD3.11,36 In keeping with this, we observed
a striking increase in superoxide production as measured
by electron spin resonance in mice following deletion of
SOD3.
Mice with embryonic deletion of SOD3 are predis-
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Figure 5. A: Effect of the SOD mimetic MnTBAP and SOD-containing micropar-
ticles on survival (A) and lung injury (B) in C57BL/6 and Tgcre/esr  ecSODloxp/loxp
mice. MnTBAP (1 mg/20 g of body weight) was dissolved in PBS and injected
intraperitoneally for 3 consecutive days before starting the tamoxifen or vehicle
injections and for 12 days thereafter. During isoflurane anesthesia, SOD-contain-
ing nanoparticles were administered intranasally (1 mg/20 g of body weight) 3
days before starting tamoxifen and vehicle injections, on the third day of treat-
ment, and 3 days after finishing treatment. B: Lungs were fixed with formalin 10%
and embedded in paraffin. Five-m slices were cut and stained with hematoxylin






























Figure 6. Effect of SOD3 deletion on blood pressure and cardiac function. Blood pressure (mmHg) measured by radiotelemetry in C57BL/6 and Tgcre/esr 
ecSODloxp/loxp mice before, during, and after treatment with either tamoxifen or vehicle is shown in A (n  6–10 per group). B: Examples of echocardiography
images obtained in C57BL/6 and Tgcre/esr  ecSODloxp/loxp mice after tamoxifen treatment for 5 days.
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prolonged periods20 or when exposed to other oxidant
injuries such as hypoxia or ozone.18,37 The histological
appearance of the lungs in these animals following ex-
posure to high oxygen has been reported to be similar to
that observed in the current study following acute dele-
tion of the gene in normoxic conditions.20 Surprisingly,
mice with embryonic SOD3 deletion tolerate exposure to
ambient oxygen, although in preliminary studies, we have
found that they have minor degrees of alveolar septal
thickening and inflammatory infiltrates that denote a mod-
erate degree of lung injury (data not shown). It is likely
that embryonic deletion of SOD3 leads to compensatory
mechanisms that allow survival despite structural
changes we observed on acute deletion of this gene.
Previous studies have supported a role for reactive
oxygen species such as superoxide in inducing chemo-
taxis of inflammatory cells38 and that SOD3 prevents
inflammation.39,40 Our fluorescence cell sorting analysis
showed that acute deletion of SOD3 leads to a striking
pulmonary infiltration of various inflammatory cells.
Among T cell subtypes, the increase in CD8 cells was
greater than CD4 cells. In keeping with these findings,
Hashimoto et al have shown that bleomycin-induced lung
injury is associated with a lymphocytic infiltrate in mice.41
These investigators have also shown high levels of mRNA
for several products of CD8 T cells, including gran-
zymes A and B, perforin, Fas, and Fas ligand in the
bronchoalveolar fluid of patients during the acute phase
of lung injury.42 These molecules participate in apoptotic
cytotoxicity induced by CD8 cells and could contribute to
lung injury. The large accumulation of granulocytes oc-
curs in numerous types in acute lung injury.43,44
As seen in Figure 4, tamoxifen injection caused a small
increase in granulocytes in wild-type mice. We consid-
ered the possibility that tamoxifen could induce an inflam-
matory response in the absence of SOD3 and that the
acute reduction in SOD3 caused by tamoxifen was not
the cause of lung damage and death. To address this, we
treated SOD3/ mice for 5 days with tamoxifen (n  6).
This caused no death or change in lung histology (data
not shown). We therefore do not believe that tamoxifen
nonspecifically caused lung damage in the absence of
SOD3 but that its effect was due to acute reduction of
SOD3.
In Tgcre/esr  ecSODloxp/loxp mice, induction of Cre-
recombinase using tamoxifen did not completely elimi-
nate SOD3 but reduced it by 50 to 60%, presumably due
to an incomplete deletion of the gene in the target tissues.
It is possible that SOD3 levels would have decreased
further; however, mice became ill generally between 3
and 7 days following the initial tamoxifen injection, and
we harvested organs at that time, such that it was impos-
sible to determine the efficacy of Cre-recombinase induc-
tion on SOD3 levels in these animals at latter times. In
Tgcre/esr  ecSODloxp/loxp mice that survived tamoxifen
injections, we found minimal (	30%) reduction of SOD3
in preliminary studies, suggesting that these animals
might have survived simply because of persistent SOD3
expression. The reason why tamoxifen had minimal effect
in these animals is unclear but might be due to technical
problems due to intraperitoneal injection or variability of
Cre-recombinase induction. Our data can also be inter-
preted as showing that as lung SOD3 levels fall, when
they reach approximately 50% of normal levels, acute
lung injury occurs. Despite this modest reduction of
SOD3, there was a striking increase in lung O2
. production
as estimated by electron spin resonance, in keeping with
the rapid kinetics of the reaction between SOD and O2
.. It
is unlikely that the lung damage occurred as a conse-
quence of tamoxifen or the vehicle used, as tamoxifen
had no effect on survival or lung histology in C57BL/6
mice or ecSODloxp/loxp mice lacking Cre-recombinase.
The fact that MnTBAP and SOD1 locally released from
microparticles could prevent mortality in these mice
strongly supports a role for O2
. in the genesis of the lung
damage. The role of MnTBAP as antioxidant has been
already demonstrated in prior studies, in which MnTBAP
has prolonged survival in SOD2-deficient mice and re-
duced injury in Paraquat-induced lung injury.45,46
Several prior studies have shown that diverse injuries
such as hyperoxia, asbestos injury, and hypoxia are as-
sociated with a decrease in lung activity and protein
levels of SOD3 ranging from 30% to 50%.16–18 In these
studies, it was not clear whether this decrease in SOD3
was the cause of lung injury or was simply a reflection of
destruction of cells that produce this enzyme. Our
present experiments indicate that a 50% decrease in
SOD3 can cause lung injury even in the absence of an
initiating insult. In addition to changes in protein levels,
hydrogen peroxide can lead to inactivation of the Cu/
ZnSODs via a reaction with the copper catalytic center of
Table 2. Gene Array in Lungs from Wild-Type Tgcre/esr 
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these enzymes.47–49 It is therefore possible that hydro-
gen peroxide generated in response to stimuli such as
infection or trauma could lead to inactivation of SOD3
without changing its protein levels.
To gain insight into mechanisms that allow survival of
mice with embryonic deletion of SOD3 that are not
present in the Tgcre/esr  ecSODloxp/loxp mice, we per-
formed gene array studies analyzing 47,000 mRNAs in
these animals. Thirty-seven genes were up-regulated by
more than twofold in the SOD3/ lungs compared to
either wild-type mice or the Tgcre/esr  ecSODloxp/loxp
mice after tamoxifen treatment. These encoded several
factors involved in cell signaling, including the transcrip-
tion factors FosB, Nr4a1, Erg1, and Etv5. FosB interacts
with the DNA-binding complex AP1 and modulates nu-
clear gene transcription.50 The transcription factor early
growth response (Erg-1) has been shown to be involved
in the tissue factor gene regulation,51 and Etv5 is a
member of the Ets transcription factor family.44 Other
cell signaling genes that are highly expressed in the
SOD3/ lungs include the FGF receptor 3, which has
been implicated in lymphatic vessel development52; the
Ras effector family member Rassf3, which can function
as a tumor suppressor53; and ARf3, a member of the
small G-protein family that is involved in epithelial cell
proliferation.54 The extracellular matrix encoding mRNAs,
utrophin, and Ndst were also increased in the SOD3/
mice compared to the other animals. Of particular inter-
est, CD59, a surface protein that conveys resistance to
compliment attack, was up-regulated about threefold in
mice with embryonic deletion of ecSOD. Another striking
finding was an increase in immunoglobulin heavy chain
VJ558 by 30-fold in the SOD3/mice and by threefold in
the Tgcre/esr  ecSODloxp/loxp mice compared to wild-
type mice. This might implicate inappropriate expression
of heavy chain in nonimmunological tissues in response
to oxidant stress.
In contrast to the rather large number of genes up-
regulated in the ecSOD/ mouse lungs, a relatively
small number were down-regulated. One notable gene
that was reduced by two- to 2.5-fold in mice with both
embryonic and acute deletion of SOD3 is Peg 3, which is
involved in tumor necrosis factor- signaling and pro-
motes p53-mediated apoptosis.55 In addition, the inter-
leukin-22 receptor was reduced by fourfold in the mice
with embryonic deletion. Interleukin-22 is a product of
CD4 T cells and is involved in autoimmune and proin-
flammatory diseases. Down-regulation of its receptor
might convey protection. Another striking finding was a
ninefold down-regulation of MID1, a microtubule-associ-
ated protein, in SOD3/ mice. This protein is involved in
formation of midline structures; however, its role in inflam-
mation has not been defined.56
The roles of these various genes in protection against
oxygen toxicity remain undefined, and a precise defini-
tion of their roles is beyond the scope of this study. It is of
interest, however, that virtually none of these are obvi-
ously involved in scavenging of reactive oxygen species
or responses to oxidant stress, while many seem to be
involved in protection against inflammatory reactions. It
might have been expected that alternate reactive oxygen
species-scavenging enzymes would be up-regulated in
SOD3/ mouse lungs, such as one of the other super-
oxide dismutases or other molecules that could react with
superoxide. This analysis emphasizes the unique as-
pects of the superoxide dismutases in that they seem to
be the only enzymes that catalytically remove the super-
oxide radical and the unique extracellular location of
SOD3, which prohibits compensation by intracellular su-
peroxide dismutases. Thus the organism is unable to
provide an alternate mode for removing extracellular su-
peroxide dismutase and therefore compensates for the
life-long loss of SOD3 by reducing inflammation. These
studies therefore emphasize the link between oxidation
and inflammation and provide insight into how mammals
respond to a loss of a particular reactive oxygen species-
scavenging enzyme.
In a prior study, we showed that mice with embryonic
deletion of SOD3 develop augmented hypertension in
response to angiotensin II infusion but had normal hemo-
dynamics at baseline.25 Given the large amount of SOD3
in vessels, we initially thought that the normal hemody-
namics at baseline was due to compensatory mecha-
nisms that could have developed in the SOD3/ mice
during development and that acute reduction of SOD3
might lead to hypertension. The limited data we obtained
in mice before death failed to reveal any increase in
blood pressure. It is difficult to exclude a role of SOD3 in
modulation of basal blood pressure based on these stud-
ies because of the limited time before pulmonary pathol-
ogy developed. A cross of our SOD3loxp/loxp mice with a
vascular smooth muscle specific Cre-recombinase could
be helpful in this regard. In preliminary studies, we found
that blood pressure does not increase in mice given
SOD-containing microparticles intranasally, suggesting
that this modest decrease in SOD3 in organs other than
the lung does not alter baseline blood pressure.
In summary, our current studies show that SOD3 is
essential for survival in the presence of ambient oxygen,
and even a modest reduction of this enzyme leads to
profound lung injury and mortality. These findings have
relevance to several causes of lung injury that are asso-
ciated with decreased SOD3 protein levels and activity,
and it is interesting to speculate that in these conditions,
the loss of SOD3 is a perpetuating factor. Moreover, in
the present study, we show that systemic treatment with
MnTBAP or local administration of SOD using novel mi-
croparticles can reduce lung damage and reduce mor-
tality. Therapies such as these might prove useful in
treating acute lung injury in humans.
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